How Covid failed to derail the FDA
Average US review times match absolute approval numbers in remaining unaffected by the Covid pandemic.
The biggest launches of 2022: a reboot
New Alzheimer’s launches are all but ruled out, so projects from Lilly, Alynlam and Roche top 2022’s biggest hopes.
